Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;23(6):721-745.
doi: 10.1111/ddg.15624. Epub 2025 May 22.

Supportive pain therapy in dermatology

Affiliations
Review

Supportive pain therapy in dermatology

Markus Werner et al. J Dtsch Dermatol Ges. 2025 Jun.

Abstract

In conservative dermatology, significant pain frequently presents as an accompanying symptom of complex and severe diseases, severely impacting patients' quality of life. Herpes zoster and pyoderma gangrenosum are two conditions commonly associated with pain. Supportive therapy refers to measures designed to alleviate and improve disease-related symptoms, such as pain, in addition to disease-specific treatments. This review focuses on strategies for targeted pharmacological pain management, addressing contraindications, usage restrictions, dosing, dose adjustments, and potential drug interactions. While nonopioid analgesics are central to pain management, carefully selected opioids are also utilized. However, these may negatively affect patients' well-being and treatment adherence due to side effects like constipation and nausea. As a result, a supportive adjunctive therapy to address these side effects is crucial. The principles of targeted pharmacological pain therapy, consistent with current guidelines and recommendations from professional societies, are outlined in this article for use in dermatological practice.

Keywords: herpes zoster; opioid induced constipation; pain; pain therapy; pyoderma gangraenosum; supportive therapy.

PubMed Disclaimer

Similar articles

References

REFERENCES

    1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Supportive Therapie bei onkologischen PatientInnen ‐ Langversion 1.3, 2020, AWMF Registernummer: 032/054OL. Available from: https://www.leitlinienprogrammonkologie.de/leitlinien/sympathetic‐therap... accessed September 7, 2023).
    1. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161:1976‐1982.
    1. Finnerup NB, Kuner R, Jensen TS. Neuropathic Pain: From Mechanisms to Treatment. Physiol Rev. 2021;101:259‐301.
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789‐1858.
    1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287‐333.